Expertise in
4
conditions

Anhui Shi

Key Laboratory Of Carcinogenesis And Translational Research, 
Beijing, CN 
Expertise in
4
conditions
Key Laboratory Of Carcinogenesis And Translational Research, 
Beijing, CN 

Overview

Anhui Shi practices practicing medicine in Beijing, China.

Shi is highly rated in 4 conditions, according to our data. Their clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Esophagitis.

They are actively involved in clinical research, co-authoring 50 peer reviewed articles and participating in 3 clinical trials.

Locations

Key Laboratory Of Carcinogenesis And Translational Research, Beijing, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: M7824, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin
Study Phase: Phase 2
A Multicenter, Prospective, Randomized, Phase III Trial Evaluating High-dose Versus Standard-dose Radiation With Concurrent Chemotherapy for Thoracic Esophageal Squamous Cell Carcinoma
A Multicenter, Prospective, Randomized, Phase III Trial Evaluating High-dose Versus Standard-dose Radiation With Concurrent Chemotherapy for Thoracic Esophageal Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: June 13, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
A Randomised, Open, Blank-controlled, Multi-centre Study of Anlotinib as Sequential Therapy in Patients With Unresectable NSCLC(Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy
A Randomised, Open, Blank-controlled, Multi-centre Study of Anlotinib as Sequential Therapy in Patients With Unresectable NSCLC(Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy
Enrollment Status: Completed
Publish Date: June 12, 2023
Intervention Type: Drug
Study Drug: Anlotinib
Study Phase: Phase 2
View 2 Less Clinical Trials

50 Total Publications

Impact of chemotherapy dose reduction during concurrent chemoradiotherapy on survival outcomes in limited-stage small-cell lung cancer.
Impact of chemotherapy dose reduction during concurrent chemoradiotherapy on survival outcomes in limited-stage small-cell lung cancer.
Journal: BMC cancer
Published: April 02, 2026

Frequently Asked Questions about Anhui Shi

Is Anhui Shi a top-rated expert for Small Cell Lung Cancer (SCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Anhui Shi is classified as an Advanced expert for Small Cell Lung Cancer (SCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Anhui Shi participate in research or clinical trials?

Yes. Anhui Shi has published 50 articles and abstracts on conditions like Small Cell Lung Cancer (SCLC). You can view a list of Anhui Shi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Shi's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile